The reality of LOH-symptoms

Size: px
Start display at page:

Download "The reality of LOH-symptoms"

Transcription

1 The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands

2 The reality of LOH symptoms

3 male external & internal genitalia Testosterone Corona et al., J Sex Med 2011;8:3869.

4 Age, < 50 y, N=869 Age >50 y, N=606 Araujo et al. J Clin Endocrinol Metabolism 2007,

5 The reality of LOH symptoms

6 Three less specific symptoms of LOH Osteoporosis Overweight Depression and: Mortality!

7 T is metabolized to 5alfaDHT and 17betaEstradiol

8 Low trauma fracture, low bone mineral Density 1.Osteoporosis in men 10 years later than in women 2.More hipfractures in men with low testosteron High costs because of hip- and lumbar spine fractures Meier C, Arch Int Med 2008;168;

9 Three less specific symptoms of LOH Osteoporosis Overweight Depression and: Mortality!

10 European Male Aging Study (EMAS) Relation between Age, BMI and Testosterone Wu FCW et al. J Clin Endocrin Metab 93(7): (2008)

11 The risks of a high BMI: 30kg/m 2 = Obese Cohort study :6502 men born in 1955 in Denmark Follow up :33 years Normal weight: 5407 men =83% Underweight : 353 men =5% Overweight : 639 men=10% Obese : 97 men=1,5% Schmidt M, BMJ Open 2013:3(4)

12 Results Danisch Study, Schmidt, BMJ Open 2013 % of DM-2, hypertension, myocardial infarction, venous tromboembolism or death before the age of 55 years Normal weight : 20 % Overweight : 31 % Obese men : 48%

13 Results Danisch Study, Schmidt, BMJ Open 2013 Event Rate : DM-2 RR MI Tromboemb. Death Normal weight : Overweight : 3,1 2 1,1 0,9 0,9 Obese men : 8,2 2,0 2,5 4,7 2,1 Absolute risk increase of 30% in obese men

14 Association Mortality with Overweight and Obesity Meta-analysis by K. Flegal, JAMA, 2013, 309, PubMed and EMBASE search articles, - 97 elegible : combining a sample size of: - 2,88 million individuals deaths

15 Association Mortality with Overweight and Obesity Flegal, K, JAMA 2013

16 Lower mortality in overweight and grade 1 obese men/women Possible explanations: -Earlier presentation of heavier patients -Greater likelihood of receiving optimal medical treatment -Benefits of higher metabolic reserves Flegal K, JAMA 2013 ; 309

17 Low Testosterone as a risk factor for CV-Mortality Meta-analysis by Corona G, Eur J of Endocr, 2011, 165, Medline search articles, - 70 elegible

18 Lower T as a risk factor for (cardiovascular)mortality Corona G, 2011

19 LOH and all-cause mortality in men with DM-2 Muraleedharan V, T Hugh Jones, Nottinghamshire, UK -6-year follow up -n=581 men with type 2 diabetes -Mortality rates compared between: TT 10,4 nmol/l : n=343: 9% TT 10,4 nmol/l : n=238: 17,2% Eur J Endocrin,

20 Figure 1 Multivariate-adjusted survival curves using Cox regression model for all-cause mortality based on total testosterone (TT). Hazard Ratio: % 17,2% Muraleedharan V et al. Eur J Endocrinol 2013;169: European Society of Endocrinology

21 Figure 3 Multivariate-adjusted survival curves using Cox regression model for treated and untreated groups compared with those with normal testosterone. 64 with TRT: 9,3% Effect of TRT on mortality in 238 men with low T Mean duration of TRT: 41 months Hazard ratio:2,3 for decreased survival 340 normal TT: 9,1% 174 without TRT: 20,1% Muraleedharan V et al. Eur J Endocrinol 2013;169: European Society of Endocrinology

22 TRT increases the risk of a cardiovascular mortality 4 studies: 1.Basaria, NEJM 2010;363; Xu, BMC Medicine 2013; 11: Vigen, JAMA 2013; 310: Finkle, PLoS ONE 2014;9(1); e85805 Generated considerable concern regarding safety of TRT among global medical community and lay public

23

24 Death by Testosterone? We Think Not! The Journal of Sexual Medicine Volume 11, Issue 3, pages , 4 MAR 2014 DOI: /jsm

25 Overview of the literature by Traish J Sex Med 2014

26 Three less specific symptoms of LOH Osteoporosis Overweight Depression and: Mortality!

27 2-year incidence diagnosis depression ICD-9-CM Increased incidence of depression in hypogonadism Shores et al Arch Gen Psychiat 2004 N = 278 men > 45 years initially without depression Total T nmol / L

28 Symptomprävalenz % Depression Zitzmann et al. JCEM Overall Somer s d: p < T<8 T:8-10 T:10-12 T:12-15 T:15-20 T 20 Sextile Total T (nmol/l) n (patients) (Total n = 434)

29 The reality of LOH-symptoms Symptoms not very specific, but Symptoms necessary for the Diagnosis LOH Symptoms are relatively mild, insidious and difficult to recognize but Often bothersome, and frustrating because of an overall decrease of the quality of life (until death!)

30 Are symptom questionnaires of any help? ADAM questionnaire 2000 Good sensitivity AMS-questionnaire 2004 Low specificity NERI Hypogonadism screener 2011 ANDROTEST /70%

31 AMS questionnaire 17 questions 5 points each In total 85 points

32 Frequency distribution of complaints by AMS in a normal population vs patients before and after 12 weeks of TRT no/little mild moderate severe 10 0 standard population before therapy after therapy Moore C et al, Eur Urol 46:80-87(2004)

33 New Definition of LOH: EMAS, Wu,NEJM 2010 Syndromic association between Triad of sexual symptoms and Biochemical condition -Low libido -Reduced spontaneous erections -Reduced sex-related erections -Morning Total T < 11 nmol/l (<3.1ng/ml) -Free T < 222,2 pmol/l (<64 pg/ml)

34 So, are the symptoms real?? Answer: Yes, they are Are the symptoms specific for LOH? No, only for a triad of three sexual symptoms

35 Is this the End? Pieter Brueghel de Oude

36 Or like this? Mick Jagger, 70 years The End

37 Gender as a risk factor for cardiovascular mortality In General in Europe: before 65 years before 75 years Men 1 in 8 1 in 4 Women 1 in 20 1 in 6 Atlas of Health in Europe, WHO 2008

PRISM Bruges June Herman Leliefeld Urologist. The Netherlands

PRISM Bruges June Herman Leliefeld Urologist. The Netherlands PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up

More information

Update on diagnosis and complications of adult and elderly male hypogonadism

Update on diagnosis and complications of adult and elderly male hypogonadism Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism

More information

Does TRT Induce Prostate Cancer?

Does TRT Induce Prostate Cancer? Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there

More information

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY

More information

Testosterone Therapy in Men An update

Testosterone Therapy in Men An update Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None

More information

Outline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD

Outline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department

More information

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of

More information

Disclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI

Disclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI Testosterone, the FDA and CVD Risk Controversies Faculty Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI 2 Disclosures Matt Rosenberg, MD serves on the advisory board for Bayer,

More information

Disclosures. Advisory Boards 6/10/2014

Disclosures. Advisory Boards 6/10/2014 Massachusetts Medical Society 12 th annual Men s Health Symposium 11 June 2014 Testosterone and Cardiovascular Disease Where Does The Real Answer Lie? Andre Guay MD, FACP, FACE, IF (Ret) Director, Center

More information

Point-Counterpoint: Late Onset Hypogonadism (LOH)

Point-Counterpoint: Late Onset Hypogonadism (LOH) Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx

More information

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics

More information

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone

More information

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd. 4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant

More information

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01.

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01. Testosterone Therapy and Mortality Risk Michael L. Eisenberg, MD 1, Shufeng Li, MS 2, Danielle Herder, MD 3, Dolores J. Lamb, PhD 4, and Larry I. Lipshultz, MD 4 1 Assistant Professor, Departments of Urology

More information

Low T? Late Onset Hypogonadism

Low T? Late Onset Hypogonadism University of Vermont ScholarWorks @ UVM Family Medicine Clerkship Student Projects College of Medicine 2014 Low T? Late Onset Hypogonadism Cheng-Wei Huang University of Vermont Follow this and additional

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Testosterone and PDE5 inhibitors in the aging male

Testosterone and PDE5 inhibitors in the aging male Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005

More information

Erectile Dysfunction, Cardiovascular Risk and

Erectile Dysfunction, Cardiovascular Risk and Erectile Dysfunction, Cardiovascular Risk and Testosterone National Lipid Association (NLA) 2016 Fall Clinical Update August 26-28, 2016 Amelia Island, Fl Robert A. Kloner MD, PhD Director of the Cardiovascular

More information

Present and future association between obesity and hypogonadism in Italian male

Present and future association between obesity and hypogonadism in Italian male ORIGINAL PAPER DOI: 10.4081/aiua.2014.1.26 Present and future association between obesity and hypogonadism in Italian male Valentina Boddi 1, Valeria Barbaro 2, Paul Mc Nieven 3, Mario Maggi 1, Carlo Maria

More information

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.

More information

NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS

NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS 2017 UPDATE FDUS Martin Miner MD Clinical Professor of Family Medicine and Urology Co-Director The Men s Health Center The Miriam Hospital Warren Albert School

More information

Take-Home Messages: Androgens

Take-Home Messages: Androgens Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical

More information

Late onset hypogonadism

Late onset hypogonadism Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs

More information

BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE

BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation

More information

Vitamin D supplementation of professionally active adults

Vitamin D supplementation of professionally active adults Vitamin D supplementation of professionally active adults VITAMIN D MINIMUM, MAXIMUM, OPTIMUM FRIDAY, SEPTEMBER 22 ND 2017 Samantha Kimball, PhD, MLT Research Director Pure North S Energy Foundation The

More information

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008 BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology

More information

Metastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942

Metastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Prostate cancer Metastatic disease 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Impact of early prostate cancer 12 10 8 6 4 2 0 70-80 years 60-70 years

More information

Why Do We Treat Obesity? Epidemiology

Why Do We Treat Obesity? Epidemiology Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population

More information

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated. Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology

More information

Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA

Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy

More information

Emerging Areas Relating Vitamin D to Health

Emerging Areas Relating Vitamin D to Health ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The

More information

Hypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018

Hypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018 Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017

More information

HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)

HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION

More information

FOR CONSUMERS AND PATIENTS

FOR CONSUMERS AND PATIENTS AVAILABILITY OF VITAMIN D FOR CONSUMERS AND PATIENTS Prof. Heike A. Bischoff-Ferrari, MD, DrPH Centre on Aging and Mobility, University of Zurich Dept. of Rheumatology, University Hospital Zurich Overview

More information

Vitamin D and Calcium Therapy: how much is enough

Vitamin D and Calcium Therapy: how much is enough Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS

More information

The Endocrine Society Guidelines

The Endocrine Society Guidelines Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS

More information

Testosterone therapy in the new era of Food and Drug Administration oversight

Testosterone therapy in the new era of Food and Drug Administration oversight Review Article Testosterone therapy in the new era of Food and Drug Administration oversight Bethany Desroches 1, Taylor P. Kohn 2, Charles Welliver 3, Alexander W. Pastuszak 1,4 1 Scott Department of

More information

TRT and localized protate cancer

TRT and localized protate cancer TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be

More information

How to treat: TRT modalities and formulations

How to treat: TRT modalities and formulations How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement

More information

Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto

Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis

More information

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health

More information

Cardiac Safety Signals: Case Examples

Cardiac Safety Signals: Case Examples Cardiac Safety Signals: Case Examples Testosterone Peripherally-acting mu-receptor antagonist PAMORAs Dabigatran (Pradaxa) 2 Testosterone Testosterone replacement therapy is approved for men with low levels

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B

More information

Schöttker et al. BMC Medicine (2016) 14:26 DOI /s

Schöttker et al. BMC Medicine (2016) 14:26 DOI /s Schöttker et al. BMC Medicine (2016) 14:26 DOI 10.1186/s12916-016-0570-1 RESEARCH ARTICLE HbA 1c levels in non-diabetic older adults No J-shaped associations with primary cardiovascular events, cardiovascular

More information

Systematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)

Systematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%) Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284

More information

Primary Care Updates ACP conference 2015

Primary Care Updates ACP conference 2015 Primary Care Updates ACP conference 2015 Richard Rose, MD FACP Assistant Professor University of Utah Department of General Internal Medicine VAMC - Internal Medicine Nothing to disclose Conflicts of interest

More information

Vascular Diseases. Overview: Selected Slides

Vascular Diseases. Overview: Selected Slides Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates

More information

Osteoporosis in Men Professor Peter R Ebeling

Osteoporosis in Men Professor Peter R Ebeling Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental

More information

Testosterone and obesity. Referent Prof. Dr. Michael Zitzmann

Testosterone and obesity. Referent Prof. Dr. Michael Zitzmann Testosterone and obesity Referent Prof. Dr. Michael Zitzmann Transparenzinformation arztcme Die Bundesärztekammer und die Landesärztekammer Hessen fordern zur Schaffung von mehr Transparenz beim Sponsoring

More information

Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang

Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University

Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a

More information

Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY

Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two

More information

Ian Eardley Department of Urology, Leeds Teaching Hospital Trust

Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men

Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan

More information

The clinical importance of testosterone in men with type 2 diabetes

The clinical importance of testosterone in men with type 2 diabetes 22 The clinical importance of testosterone in men with type 2 diabetes GEOFF HACKETT Although the association of low testosterone with type 2 diabetes is well established, testosterone levels are not routinely

More information

PCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS

PCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal

More information

O futuro da Ciência e dos Dados Científicos

O futuro da Ciência e dos Dados Científicos IX Congresso Nacional O futuro da Ciência e dos Dados Científicos Prof. Luis A. Moreno Determinants and risk factors for cardiovascular diseases (Tzoulaki I et al. Circulation 2016; 133: 2314-2333) Adjusted

More information

Relative Risk of Major Risk of Chronic Major Disease Catego ries, by Gender and Gender and verag e Drinkin e Dr g Catego Females Males Disease Disea

Relative Risk of Major Risk of Chronic Major Disease Catego ries, by Gender and Gender and verag e Drinkin e Dr g Catego Females Males Disease Disea 38 th IMAG Conference, Amsterdam, October 13-14, 14, 2014 International Meeting on Alcohol and Global Health Overview: All-Cause Mortality Wolfgang Koenig MD, FRCP, FESC, FACC, FAHA Dept. of Internal Medicine

More information

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV

More information

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,

More information

Nutritional Considerations with Obesity and Bariatric Surgery. Presented by Dr. Ron Grabowski

Nutritional Considerations with Obesity and Bariatric Surgery. Presented by Dr. Ron Grabowski Nutritional Considerations with Obesity and Bariatric Surgery Presented by Dr. Ron Grabowski January 25, 2010 Nutritional Considerations with Obesity and Bariatric Surgery Presented by Dr. Ron Grabowski

More information

Supplemental tables: Abbreviations:

Supplemental tables: Abbreviations: Supplemental tables: Abbreviations: Osteoprotegerin (OPG), Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL), fibroblast growth factor-23 (FGF-23), C-terminal cross-linked telopeptide of type-i

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

Testosterone and the Prostate

Testosterone and the Prostate Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University

More information

Metabolically healthy obesity and NAFLD

Metabolically healthy obesity and NAFLD News & Views Metabolically healthy obesity and NAFLD Giovanni Targher and Christopher D. Byrne Giovanni Targher is at the Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University

More information

Every obese male with type 2 diabetes should be screened for hypogonadism

Every obese male with type 2 diabetes should be screened for hypogonadism Every obese male with type 2 diabetes should be screened for hypogonadism FOR Professor T Hugh Jones Consultant Physician & Endocrinologist, Robert Hague Centre for Diabetes and Endocrinology, Barnsley

More information

OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW

OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through

More information

SMSNA Hypogonadism Colloquium: Update

SMSNA Hypogonadism Colloquium: Update SMSNA Hypogonadism Colloquium: Update Arthur L. (Bud) Burnett, M.D., M.B.A., F.A.C.S. Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute Johns Hopkins Medicine

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

What Is the Low T Syndrome? Is Testosterone Supplementation Safe?

What Is the Low T Syndrome? Is Testosterone Supplementation Safe? What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive

More information

Testosterone Deficiency Syndrome. Time for Proper Personalised Care

Testosterone Deficiency Syndrome. Time for Proper Personalised Care Prof Geoffrey Hackett Good Hope Hospital Sutton Coldfield Testosterone Deficiency Syndrome Time for Proper Personalised Care BSSM Testosterone Guidelines 2017 www.bssm.org.uk Recommendations Diagnosis

More information

Register now at

Register now at Register now at www.issuesandanswers.org Inspiring programme, great speakers & 6 CPD points! MAKING BEST PRACTICE EVERYDAY PRACTICE Sex, hormones & the heart Professor Mike Kirby FRCP University of Hertfordshire

More information

Risk Stratification of Surgical Intensive Care Unit Patients based upon obesity: A Prospective Cohort Study

Risk Stratification of Surgical Intensive Care Unit Patients based upon obesity: A Prospective Cohort Study Risk Stratification of Surgical Intensive Care Unit Patients based upon obesity: A Prospective Cohort Study DR N O M A N S H A H Z A D R E S I D E N T G E N E R A L S U R G E R Y A G A K H A N U N I V

More information

9/2/2016. Faculty. Learning Objectives. Disclosures. Prevalence of Hypogonadism. Prevalence of HG (cont)

9/2/2016. Faculty. Learning Objectives. Disclosures. Prevalence of Hypogonadism. Prevalence of HG (cont) Faculty Testosterone Replacement Therapies: Mitigating Cardiometabolic Risks Associated with Hypogonadism Pamela Ellsworth, MD Professor of Urology University of Massachusetts Medical School Vice Chair,

More information

ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN

ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency

More information

THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION

THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION Aksam A. Yassin MD PhD EdD FEBU Professor of Urology & Human Sexuality Institute of Urology & Andrology, Segeberger

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

RESEARCH. Dagfinn Aune, 1,2 Abhijit Sen, 1 Manya Prasad, 3 Teresa Norat, 2 Imre Janszky, 1 Serena Tonstad, 3 Pål Romundstad, 1 Lars J Vatten 1

RESEARCH. Dagfinn Aune, 1,2 Abhijit Sen, 1 Manya Prasad, 3 Teresa Norat, 2 Imre Janszky, 1 Serena Tonstad, 3 Pål Romundstad, 1 Lars J Vatten 1 open access BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants Dagfinn Aune, 1,2 Abhijit

More information

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency

More information

Testosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E

Testosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a

More information

HORMONE THERAPY IN AGING MALE ATHLETES

HORMONE THERAPY IN AGING MALE ATHLETES DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the

More information

Vitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016

Vitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016 Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal

More information

Testosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands

Testosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Åsvold BO, Vatten LJ, Bjøro T, et al; Thyroid Studies Collaboration. Thyroid function within the normal range and risk of coronary heart disease: an individual participant

More information

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine

More information

Presenter Disclosure Information Karine Sahakyan, MD, PhD, MPH

Presenter Disclosure Information Karine Sahakyan, MD, PhD, MPH Presenter Disclosure Information Karine Sahakyan, MD, PhD, MPH Disclosed no conflict of interest Normal-weight central obesity and cardiovascular mortality risk in the US population K. Sahakyan, VK. Somers,

More information

SERMS, Hormone Therapy and Calcitonin

SERMS, Hormone Therapy and Calcitonin SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings

More information

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle

More information

Hypogonadism and erectile dysfunction as harbingers of systemic disease

Hypogonadism and erectile dysfunction as harbingers of systemic disease Review Article Hypogonadism and erectile dysfunction as harbingers of systemic disease Kelly A. Chiles 1,2 1 Department of Urology, George Washington University, Washington, DC, USA; 2 Weill Cornell Medical

More information

Testim 1 Gel: Review of Clinical Data

Testim 1 Gel: Review of Clinical Data European Urology Supplements European Urology Supplements 4 (2005) 24 30 Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire

More information

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen

More information

Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)

Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John

More information

Update on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA

Update on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes

More information

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D. The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,

More information

Thiazolidinediones and the risk of bladder cancer: A cohort study. R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis

Thiazolidinediones and the risk of bladder cancer: A cohort study. R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis Thiazolidinediones and the risk of bladder cancer: A cohort study R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis Study objective To investigate the risk of bladder cancer associated

More information

Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study

Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study Mahyar Etminan, 1,2, * Sean C. Skeldon, 3,4 Sheldon Larry Goldenberg, 3 Bruce Carleton, 1,2 and James M. Brophy 5 1

More information